MedTrace Logo

SEgmentectomy Versus Lobectomy in T1C Non-Small Cell Lung Cancer (SELTIC)

NCT06646770 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2024-10-17

No results posted yet for this study

Summary

The goal of this clinical trial is to investigate the role of segmentectomy in clinical T1c (2-3 cm) non-small cell lung cancer (NSCLC). The main questions we aim to answer are:

1. Is segmentectomy non-inferior to lobectomy in cT1c NSCLC in terms of overall and recurrence free survival?
2. What are the mortality and morbidity rates of segmentectomy compared to lobectomy?

Researchers will compare segmentectomy and lobectomy in terms of overall and recurrence free survival.

Participants will:

* Undergo either pulmonary lobectomy or segmentectomy with mediastinal nodal dissection
* Be followed up with a chest CT in every 3 months in first year, every 6 months in second year and every year for following 3 years

Conditions

Interventions

PROCEDURE

Segmentectomy

Pulmonary anatomic segmentectomy with mediastinal nodal dissection via VATS, RATS or open approach.

PROCEDURE

Lobectomy

Pulmonary lobectomy with mediastinal nodal dissection via VATS, RATS or open approach.

Sponsors & Collaborators

  • Istanbul University - Cerrahpasa

    lead OTHER

Principal Investigators

  • Akif Turna, MD, PhD · Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-02
Primary Completion
2030-01-31
Completion
2030-01-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06646770 on ClinicalTrials.gov